Explore the reality of schizophrenia by debunking seven myths and offering compassionate insights into this complex mental ...

Usually described as a splitting or multiple personality disorder, the concept of schizophrenia is not entirely but rather a ...

Events like one held Thursday at Fayetteville Town Center can affect how challenges surrounding schizophrenia and mental ...

Using a multi-strain probiotic formulation, researchers conducted a double-blind, randomized, placebo-controlled trial aimed at improving psychiatric and cognitive symptoms, intestinal permeability, ...

Shares of AbbVie (NYSE:ABBV) are surging 7% this morning after the pharmaceutical giant reported solid fourth quarter ...

As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is ...

treatment, and general understanding of schizophrenia, remains to be determined. It may be useful, however, for both clinicians and researchers to be aware of this phenomenon and to incorporate ...

We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...

Today, in 2025, I remember my four years homeless in Los Angeles, and am thankful for my recovery from schizophrenia.

We propose that there are existing treatments for the alleviation of negative symptoms, which may provide a novel treatment for patients with comorbid schizophrenia and cocaine abuse.

AbbVie Inc.'s stock rose 4% early Friday, after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs delivered growth needed to ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.